Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Fig. 1

Joint model diagram combining a decision-tree model with Markov model. * ROS1 determined by IHC, FISH, reflex or NGS in ‘ROS1-testing’ scenario. Not determined in ‘no-ROS1-testing’ scenario. EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; ROS1: c-ros oncogene 1; PD-L1: programmed death-ligand 1; pembro: pembrolizumab monotherapy; CT: Chemotherapy; TKI: Tyrosine kinase inhibitors; PFS: progression-free survival; PD: progression disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us